⌘ Services
mob-logo
Contact Us 800.227.0627
Contact Quote Order Login / Register

Custom Bispecific Peptide Synthesis

Design and manufacture bispecific peptides with two independent binding specificities, together with closely related dual-functional peptide conjugates for immune-cell engagement, targeted delivery, molecular imaging, diagnostics and therapeutic discovery.

Dual-Target Recognition Linear & Branched Formats Custom Linker Engineering Multifunctional Conjugates Purification & Analytical QC
Request a Quote Explore Design Options
Overview Which Architecture? Selection Guide Comparison Design Linkers Challenges Specifications Analytical QC Contact
Bispecific Peptide Engineering Platform

Two Binding Specificities in One Defined Peptide Construct

Bispecific peptides incorporate two different binding domains in one defined molecular construct. Each domain is selected to recognize a distinct receptor, ligand, protein, cell type or other biological target.

Related dual-functional peptide conjugates combine a targeting peptide with a therapeutic payload, oligonucleotide, imaging label, protein or delivery component. These constructs are closely related from an engineering and manufacturing perspective, but they are not strictly bispecific unless both domains provide independent binding specificity.

Bio-Synthesis supports sequence review, architecture selection, linker engineering, peptide synthesis, bioconjugation, purification and fit-for-purpose analytical characterization for complex dual-target constructs.

Target A Engineered Linker Target B
One construct · two independent functions
Orientation control Linker length Binding accessibility Optional cargo
Dual-Target Recognition

Engage two different receptors, ligands, proteins or cell populations with one construct.

Improved Functional Selectivity

Combine two recognition events to refine localization, binding or biological response.

Multifunctional Design

Integrate targeting with delivery, imaging, payload release or immune-cell engagement.

Modular Engineering

Optimize each binding domain, linker and conjugation site as a coordinated molecular system.

Architecture Decision Guide

Which Engineered Peptide Architecture Do You Need?

Select the classification according to biological intent. Structure describes how the molecule is built; function describes what it is designed to do.

Scientific Need Best-Fit Architecture Design Logic
Bind two different targets Bispecific peptide Two distinct recognition domains are incorporated into one construct.
Repeat one ligand for avidity Multivalent peptide Multiple copies of the same or closely related ligand increase local binding density.
Combine several immune epitopes Multiepitope peptide Different antigenic regions broaden immune recognition.
Achieve high-valency display Dendrimer peptide Generation-based branching creates many terminal groups.
Present antigens on a lysine core MAP peptide A lysine matrix supports carrier-free multivalent antigen presentation.
Terminology note: A bispecific peptide has two distinct binding specificities and may be linear, branched, cyclic, multivalent or dendritic. A targeting peptide linked to a drug, dye, oligonucleotide or protein is more precisely described as a dual-functional peptide conjugate; these adjacent formats are included because they use many of the same architecture, linker and manufacturing strategies.
Application-First Interactive Guide

Interactive Bispecific and Dual-Functional Peptide Selection Guide

Choose a construct according to the two binding specificities—or the targeting and functional components—that must be combined. Each option highlights architecture, key risks, design priorities and analytical planning.

Receptor–Receptor Bispecific Peptide

Two different peptide ligands are connected to engage separate receptors, proteins or cell populations.

Dual receptor binding Immune-cell engagement CSignaling studies
Best Fit

Dual-receptor targeting, cell bridging or pathway co-engagement.

Main Risk

One domain sterically blocks or functionally dominates the other.

Design Focus

Orientation, linker length, affinity balance and target geometry.

QC

Identity, purity and optional target-specific binding studies.

Common Formats

Linear, branched, cyclic–linear or dendritic.

Planning Question

Must both targets be engaged simultaneously, sequentially or only within the same biological compartment?

Targeting Peptide–Drug Construct

A receptor-binding peptide is combined with a therapeutic peptide or small-molecule payload using a stable or cleavable linker.

Targeted delivery Cleavable linker Payload release
Best Fit

Cell-selective delivery of a therapeutic payload.

Main Risk

Premature release, payload inactivation or poor solubility.

Design Focus

Attachment site, linker trigger, drug loading and trafficking.

QC

Intact mass, purity, loading and linker-stability assessment.

Common Formats

Linear conjugate, branched conjugate or dendrimer.

Planning Question

Should the payload remain attached or be released extracellularly, endosomally or in the cytosol?

Targeted Imaging Peptide Conjugate

A targeting domain is paired with a fluorescent dye, chelator, affinity label or other imaging component.

Fluorophore Chelator Diagnostic probe
Best Fit

Targeted imaging, biodistribution or binding studies.

Main Risk

The label changes binding, charge, hydrophobicity or clearance.

Design Focus

Label site, dye-to-peptide ratio, spacer length and spectral needs.

QC

Purity, identity, labeling stoichiometry and optical properties.

Common Formats

Single-site label, branched dual-function probe or multivalent tracer.

Planning Question

Does the imaging component need to remain exposed, shielded or positioned away from the binding domain?

Targeting Peptide–Oligonucleotide Construct

A cell- or tissue-targeting peptide is conjugated to an ASO, siRNA, PNA, PMO, aptamer or other nucleic-acid component.

ASO siRNA PNA / PMO
Best Fit

Targeted nucleic-acid delivery and cellular uptake research.

Main Risk

Charge-driven aggregation, membrane retention or impaired oligo activity.

Design Focus

Conjugation handle, linker release, charge balance and trafficking.

QC

Dual-component identity, conjugate purity and intact-product analysis.

Common Formats

Direct conjugate, cleavable conjugate or multivalent delivery system.

Planning Question

Should the oligonucleotide be released after uptake or remain permanently linked?

Targeting Peptide–Protein Construct

A peptide ligand is linked to a protein, enzyme, cytokine, antibody fragment or carrier component.

Protein conjugate Enzyme targeting Cytokine delivery
Best Fit

Protein localization, receptor targeting or multifunctional assay systems.

Main Risk

Heterogeneous attachment or loss of protein activity.

Design Focus

Site-specific chemistry, stoichiometry, orientation and protein stability.

QC

Peptide QC plus conjugate-specific characterization.

Common Formats

Site-selective conjugate, carrier conjugate or modular assembly.

Planning Question

Which attachment site preserves both peptide binding and protein function?

Design note: The two functions should be evaluated together. A construct that preserves affinity for each isolated domain may still fail if geometry, spacing, trafficking or release is not compatible with simultaneous use.
Architecture Comparison

Linear, Branched, Dendrimer, Cyclic and Hybrid Bispecific Formats

Feature Linear Branched Dendrimer Cyclic / Constrained Hybrid Conjugate
General format A–linker–B Two domains from a central core Multiple terminal functions One or both domains constrained Peptide plus non-peptide component
Relative complexity Low–moderate Moderate High Moderate–high Moderate–high
Domain accessibility Linker-dependent Often improved High but crowding-sensitive Conformation-dependent Component-dependent
Payload capacity Low–moderate Moderate High Low–moderate Variable
Best fit Simple dual-ligand constructs Independent domain display High-valency multifunctional systems Affinity and stability engineering Drug, oligo, protein or imaging integration
Main manufacturing challenge Length and sequence compatibility Branch completeness Purification and analytical complexity Cyclization and isomer control Conjugation heterogeneity
Target Combination Matrix

Common Dual-Target and Dual-Functional Combinations

Domain A Domain B Potential Research Use
Receptor ligand Second receptor ligand Cell bridging, pathway co-engagement or dual-receptor targeting
Targeting peptide Cell-penetrating peptide Cell-selective uptake and intracellular delivery
Targeting peptide Drug or therapeutic peptide Localized payload delivery
Targeting peptide ASO, siRNA, PNA or PMO Targeted nucleic-acid delivery
Targeting peptide Fluorophore or chelator Molecular imaging and biodistribution
Targeting peptide Protein, enzyme or cytokine Protein localization or receptor-specific functional delivery
Membrane-binding peptide Intracellular effector peptide Compartment-specific delivery and release
Tissue-homing peptide Lipid or nanoparticle anchor Surface-functionalized delivery systems
Design Engineering

Bispecific Construct Design Engineering

The two functional domains, the connecting architecture and the final manufacturing strategy must be optimized as one system.

Domain Orientation

Compare A–B versus B–A order and evaluate whether termini or branch placement affect binding.

Affinity Balance

Avoid one high-affinity domain dominating localization or preventing productive engagement of the second target.

Linker Geometry

Match flexibility, length and rigidity to target spacing, receptor mobility and intracellular trafficking.

Conjugation Site

Use terminal, side-chain or orthogonal handles that preserve critical binding residues and component activity.

Solubility Engineering

Review charge, hydrophobicity, aromatic content and aggregate risk across the complete construct.

Analytical Strategy

Select purification and characterization methods according to final mass, charge, branching and conjugate complexity.

Linker Engineering Guide

Choosing Linkers for Bispecific Peptide Constructs

The linker controls separation, flexibility, solubility, release and the probability that both domains remain functional.

GGGGS / (GGGGS)n
Flexible Peptide Linkers

Useful when independent domain movement and target accessibility are priorities.

EAAAK
Rigid Helical Linkers

Provide directional separation and may reduce direct domain interaction.

PEG2–PEG12
Hydrophilic PEG Spacers

Increase distance, reduce crowding and may improve solubility.

Val–Cit / GFLG
Protease-Cleavable Linkers

Consider when intracellular or lysosomal payload release is required.

Disulfide / redox
Redox-Sensitive Linkers

Enable reduction-responsive release in suitable biological environments.

Azide–DBCO / TCO–Tetrazine
Bioorthogonal Assembly

Support modular conjugation of separately manufactured components.

Important: Linker selection should be based on the complete construct, target geometry, intended compartment, release mechanism and synthesis route—not on linker name alone.
Research Applications

Applications for Bispecific and Dual-Functional Peptide Constructs

The following non-confidential examples illustrate the types of design problems that can be evaluated. Final feasibility depends on sequence, payload, valency, purity and scale.

Oncology Research
  • Dual tumor-marker targeting
  • Immune-cell recruitment
  • Targeted therapeutic delivery
Targeted Delivery
  • Cell-selective uptake
  • Endosomal or cytosolic release
  • Peptide, drug and oligo payloads
Molecular Imaging
  • Targeted fluorescent probes
  • Chelator-functionalized tracers
  • Biodistribution studies
Immunology & Diagnostics
  • Cell-bridging constructs
  • Dual-analyte recognition
  • Multiparameter assay development
Design Risk Review

Common Bispecific Design and Manufacturing Challenges

A
Domain Interference

One binding domain may mask, distort or sterically obstruct the other.

B
Unbalanced Affinity

A dominant high-affinity domain can prevent productive dual-target engagement.

C
Incorrect Linker Length

Short linkers can create steric restriction; overly long linkers can reduce effective co-engagement.

D
Hydrophobicity and Aggregation

Combining two active domains and a payload can substantially change solubility and recovery.

E
Conjugation Heterogeneity

Non-site-specific reactions can generate multiple positional or loading variants.

F
Premature Payload Release

Cleavable systems must remain stable during manufacture, storage and circulation.

G
Purification Complexity

Closely related incomplete products or unconjugated components may be difficult to resolve.

H
Analytical Compatibility

Large, branched or highly charged conjugates may require complementary characterization methods.

Manufacturing Strategy

From Molecular Design to a Characterized Product

Target & Sequence Review

Define each target, binding domain, intended biological relationship and sequence constraints.

Architecture & Linker Engineering

Select linear, branched, cyclic, dendritic or hybrid assembly and define domain orientation.

Synthesis, Conjugation & Purification

Use direct or modular assembly with project-specific purification and intermediate controls.

Analytical Characterization

Confirm identity, purity, conjugation status and additional attributes appropriate to the construct.

Typical Project Configuration

Typical Specifications and Available Options

Design Element Available Options Planning Notes
Architecture Linear Branched Cyclic Dendrimer Hybrid Selected according to geometry, accessibility, payload and manufacturability.
Functional Domains Peptide A + peptide B, targeting peptide + CPP, receptor ligand + cargo Provide sequences and intended targets or functions.
Linkers Flexible, rigid, PEG, cleavable and bioorthogonal Linker selection depends on target spacing and release requirements.
Integrated Components Drug, oligonucleotide, protein, dye, chelator, lipid or polymer Site-specific placement should be defined during design review.
Purification Preparative RP-HPLC, ion exchange, SEC or combined methods Method selection depends on mass, charge, hydrophobicity and heterogeneity.
Analytical QC Analytical HPLC/UPLC, LC-MS, MALDI-TOF and component-specific testing Final methods are selected according to construct compatibility.
Scale Research quantities through larger custom manufacturing Scale-up is subject to architecture, purity and conjugation feasibility.
Fit-for-Purpose Analytical Strategy

Analytical Characterization for Complex Bispecific Constructs

Analytical methods should be selected according to the final architecture, molecular size, conjugation chemistry and intended use. Not every method is required for every project.

HPLC or UPLC
Assesses chromatographic purity and helps resolve closely related synthesis, coupling or conjugation by-products.
Mass Spectrometry
Supports identity confirmation by LC-MS, MALDI or another platform selected for the molecular size and composition.
SEC or Size-Based Analysis
May be used for larger constructs to evaluate aggregate formation, oligomeric species or size distribution.
UV/Visible Analysis
Supports characterization of dye-, chromophore- or chelator-containing constructs and may assist with labeling assessment.
Conjugation or Loading Assessment
Evaluates attachment status, loading distribution or component ratio when the final product includes a non-peptide cargo.
Project-Specific Testing
Additional methods can be considered for solubility, composition, counterion, residuals or other defined product attributes.
Planning note: Biological binding or potency assays are not interchangeable with physicochemical release testing. Functional assays should be defined separately according to the target system and research objective.
Compatible Functional Components

Compatible Components for Bispecific and Dual-Functional Peptides

Bispecific and dual-functional peptide constructs can combine two recognition domains or integrate a targeting peptide with a therapeutic, diagnostic, delivery or analytical component. The categories below show common design options without limiting the final architecture.

Targeting & Binding Modules

Provide molecular recognition, tissue selectivity or interaction with a second biological target.

  • Receptor-Binding Peptides
  • Tumor-Homing Peptides
  • Cell-Penetrating Peptides (CPPs)
  • Immune-Modulating Peptides
  • Protein-Binding Peptides
  • Antibody-Mimetic Peptides
  • Enzyme-Binding Peptides
  • Other Application-Specific Ligands

Therapeutic & Analytical Payloads

Add therapeutic activity, imaging capability or a measurable analytical signal.

  • Therapeutic Peptides
  • Small-Molecule Drugs
  • Cytotoxic Payloads
  • Fluorescent and Near-IR Labels
  • PET/SPECT Chelators
  • Stable Isotope Labels
  • Proteins, Enzymes and Cytokines
  • Reporter Molecules and Nanoparticles

Delivery & Molecular Engineering

Control spacing, conjugation, solubility, trafficking or triggered release.

  • PEG and Hydrophilic Spacers
  • Lipid Modifications
  • ASO and siRNA Conjugates
  • PNA and PMO Conjugates
  • Click Chemistry Handles
  • Protease- or Redox-Cleavable Linkers
  • Protein and Polymer Conjugates
  • Branched and Dendrimer Scaffolds

Custom Architectures Beyond These Examples

Bio-Synthesis can review novel combinations of targeting ligands, peptide domains, oligonucleotides, proteins, imaging agents, drugs, cleavable linkers and synthetic scaffolds. Each construct is evaluated for synthesis feasibility, component orientation, purification strategy, analytical characterization and intended biological use.
Pre-quote design review available: Bio-Synthesis can evaluate domain orientation, linker strategy, architecture, conjugation chemistry, solubility, purification and analytical QC before quotation.
Design Consultation & Quote

Discuss Your Bispecific Peptide Design

Every bispecific peptide project begins with defining two independent biological functions. Our scientists can help evaluate construct architecture, domain orientation, linker design, conjugation strategy, purification and analytical characterization to support manufacturability and downstream performance.
Request a Quote Speak to a Scientist

Need help before quoting?

Email: info@biosyn.com
Phone: 800-227-0627 (US/CAN)
Phone: +001-972-420-8505 (INT)

Information for Design Review

  • Both peptide sequences or binding domains
  • Target proteins, receptors or cell types
  • Preferred architecture and orientation
  • Linker or release requirements
  • Functional payloads or conjugates
  • Quantity, purity and analytical QC

What We Review

Our scientists review dual-target logic, domain accessibility, linker selection, conjugation site, synthesis feasibility, purification strategy and analytical characterization.

Quality Systems

Quality Systems & Manufacturing Support

QMS

ISO-Supported Peptide Manufacturing

Custom bispecific peptides, branched constructs, modified peptides and peptide conjugates with controlled synthesis, purification, analytical QC, documentation and project-specific packaging.

ISO 9001:2015 Quality management system
ISO 13485:2016 Medical-device quality framework
ISO 14001 Environmental management system
Analytical QC HPLC/UPLC, MS where compatible, purity assessment and COA

Bispecific Peptide Synthesis FAQ

FAQ

What is a bispecific peptide?
A bispecific peptide contains two different binding domains designed to recognize two independent biological targets. A targeting peptide linked to a drug, dye, oligonucleotide or protein is more precisely described as a dual-functional peptide conjugate unless the attached component also provides a second binding specificity.
How is a bispecific peptide different from a multivalent peptide?
Multivalent peptides commonly repeat the same ligand to increase avidity. Bispecific peptides contain two different specificities or functions.
Can a bispecific peptide be linear or branched?
Yes. Two binding domains can be incorporated into linear, branched, cyclic, dendritic or hybrid architectures, provided both domains remain accessible and functional.
How should the linker be selected?
Linker choice depends on target spacing, domain orientation, flexibility, solubility, trafficking and whether component release is required.
Can one domain be a drug, dye or oligonucleotide?
Yes. A targeting peptide can be combined with small molecules, fluorophores, chelators, proteins, ASOs, siRNAs, PNA, PMO and other components, subject to feasibility review. These products are generally classified as dual-functional peptide conjugates rather than strict bispecific peptides.
Can Bio-Synthesis make cleavable bispecific constructs?
Protease-sensitive, redox-sensitive and other cleavable linker strategies can be evaluated according to the intended release environment.
How are bispecific constructs purified?
Purification may use preparative RP-HPLC, ion exchange, SEC or combined approaches according to size, charge, hydrophobicity and heterogeneity.
What analytical methods are available?
Typical characterization may include analytical HPLC or UPLC, LC-MS, MALDI-TOF and component-specific testing when compatible.
What information is needed for a quotation?
Provide both domain sequences, target information, preferred architecture, linker requirements, payloads, quantity, purity and analytical needs.
Can Bio-Synthesis support scale-up?
Projects can be reviewed from research quantities through larger custom manufacturing, subject to architecture, purification and conjugation feasibility.
More FAQsAll FAQs
Scientific Background & Recommended Reading

Recommended Reading

Selected background references on therapeutic peptides, multivalent ligand design, targeted delivery and peptide conjugation.

  1. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. 2015.
  2. Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorganic & Medicinal Chemistry. 2018.
  3. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chemical Biology & Drug Design. 2013.
  4. Mammen M, Choi SK, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angewandte Chemie International Edition. 1998.
  5. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discovery Today. 2010.

Note: References are provided for scientific background. Final bispecific peptide constructs should be evaluated for target biology, domain orientation, linker geometry, conjugation chemistry, solubility, manufacturability, purification and analytical characterization.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45 years of delivering high-quality, fast, and scalable synthetic biology solutions.

Greetings, Researchers,

Please be advised that any information, guidelines, write-ups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the design of products intended for their experiments before submitting
their designs to Biosynthesis for production feasibility review.
Thank you for your understanding.

Quick Links